AVROBIO is a clinical-stage gene therapy company to treat rare diseases following a single dose worldwide.
AVRO just released positive data on their Phase 1/2 trial testing the safety and efficacy of AVR-RD-04.
73.42% of the shares are controlled by institutional investors, which gives me a lot of trust in the company.
JPMorgan Chase and BlackRock Inc. have...
